Glimepirid Zentiva (Glimepiride)

Glimepirid Zentiva is indicated for the management of blood glucose levels in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

• Used when diet, exercise, and lifestyle changes alone do not achieve target glycaemic control.
• May be combined with metformin or other oral antidiabetic agents.
• Helps reduce fasting and post‑prandial blood glucose concentrations.
• Often prescribed after other first‑line therapies have been evaluated.
• Can be part of a step‑wise intensification strategy for progressive diabetes management.

Glimepirid Zentiva may cause a range of side effects, most of which are mild and transient, while serious reactions are less common but require prompt medical attention.

Common

• Mild hypoglycaemia, especially if meals are missed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.

Serious

• Severe hypoglycaemia with confusion, seizures, or loss of consciousness.
• Allergic reactions such as rash, itching, or swelling of the face and throat.

Before starting Glimepirid Zentiva, patients should consider several safety factors to minimise risks and optimise therapeutic outcomes.

• Assess renal and hepatic function, as impairment may affect drug clearance.
• Review history of cardiovascular disease, since sulfonylureas can influence cardiac metabolism.
• Monitor blood glucose regularly to detect hypoglycaemia early.
• Use caution in elderly patients who may be more sensitive to insulin‑secretagogue effects.
• Discuss any pregnancy or breastfeeding plans with a healthcare professional.
• Avoid abrupt discontinuation without medical guidance to prevent rebound hyperglycaemia.

Glimepirid Zentiva can interact with several drug classes, altering its efficacy or increasing the risk of adverse events.

Avoid

• Concurrent use of other sulfonylureas or insulin, which may cause severe hypoglycaemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels.
• High‑dose salicylates, which may potentiate hypoglycaemic effects.

Use with caution

• Beta‑blockers, which can mask hypoglycaemia symptoms.
• Thiazide diuretics, as they may affect glucose tolerance.
• ACE inhibitors or ARBs, requiring monitoring of renal function and electrolytes.